Know Your PR Status

Up to 70% of all breast, ovarian, and endometrial cancers express the progesterone receptor (PR) and are thus said to be PR+.

The progesterone receptor belongs to the steroid receptor family, a subset of the nuclear receptor family, and is the mediator of progesterone action.  PR is an oncogenic transcription factor that is activated by progesterone and that plays a key role in hormonally-regulated tissues such as breast.  The PR is expressed in normal cells and in certain malignant tissues, mediating the effects of progesterone by association with a range of co-regulatory proteins and binding to specific target sequences in progesterone-regulated gene promoters.  

If your cancer is PR+,  Apristor could be an option for you.

Learn About Apristor >